The increase in price target from $17 to $24 by Stifel indicates a positive outlook on Tandem Diabetes Care's stock, suggesting potential upside. However, the Hold rating implies that the stock might not significantly outperform the market in the short term. Investors might see this as a sign of stability with potential for growth, leading to a positive short-term impact on the stock price.